Goelzer Investment Management Inc. Lowers Position in IQVIA Holdings Inc. $IQV

Goelzer Investment Management Inc. trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 75.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,713 shares of the medical research company’s stock after selling 14,598 shares during the quarter. Goelzer Investment Management Inc.’s holdings in IQVIA were worth $895,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Artisan Partners Limited Partnership acquired a new stake in shares of IQVIA during the second quarter valued at about $515,772,000. Norges Bank purchased a new position in shares of IQVIA during the 2nd quarter worth approximately $270,160,000. AQR Capital Management LLC raised its position in IQVIA by 130.2% in the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after purchasing an additional 879,701 shares during the period. Laurel Wealth Advisors LLC lifted its stake in IQVIA by 15,755.2% during the second quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock worth $122,857,000 after purchasing an additional 774,681 shares in the last quarter. Finally, Nordea Investment Management AB boosted its position in shares of IQVIA by 41.7% during the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after buying an additional 606,391 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 1.7%

Shares of IQVIA stock opened at $224.44 on Tuesday. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $234.29. The company has a market capitalization of $38.22 billion, a P/E ratio of 30.79, a P/E/G ratio of 2.47 and a beta of 1.37. The company has a 50 day moving average of $219.47 and a 200 day moving average of $193.38.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. The business had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company’s revenue was up 5.2% on a year-over-year basis. During the same period last year, the business earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IQV has been the topic of several research analyst reports. UBS Group increased their target price on IQVIA from $225.00 to $250.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. JPMorgan Chase & Co. increased their price target on shares of IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. TD Cowen cut shares of IQVIA from a “buy” rating to a “hold” rating and lifted their price objective for the company from $206.00 to $215.00 in a report on Monday, November 3rd. Citigroup increased their target price on shares of IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a report on Wednesday, October 29th. Finally, Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $243.19.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.60% of the stock is owned by company insiders.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.